Methods for treating lymphoma

1. A method of treating a T-cell lymphoma in a human patient in need thereof, comprising administering to the patient an effective amount of cerdulatinib or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the T-cell lymphoma is relapsed or refractory T-cell lymphoma.

3. The method of claim 1 , wherein the T-cell lymphoma has not been previously treated with an agent for treating T-cell lymphoma.

4. The method of claim 1 , wherein the T-cell lymphoma is selected from peripheral T-cell lymphomas, angioimmunoblastic T-cell lymphoma, follicular T-cell lymphoma, anaplastic large cell lymphoma, enteropathy-associated T-cell lymphoma, adult T-cell leukemia/lymphoma, T-cell leukemia, nasal NK/T-cell lymphoma, hepatosplenic T-cell lymphoma, and cutaneous (skin) T-cell lymphoma.

5. The method of claim 1 , wherein the T-cell lymphoma is relapsed or refractory peripheral T-cell lymphoma.

6. The method of claim 1 , wherein the T-cell lymphoma is angioimmunoblastic lymphoma.

7. The method of claim 1 , wherein the T-cell lymphoma is anaplastic large cell lymphoma.

8. The method of claim 1 , wherein the T-cell lymphoma is hepatosplenic T-cell lymphoma.

9. The method of claim 1 , wherein the T-cell lymphoma is enteropathy-associated T-cell lymphoma.

10. The method of claim 1 , wherein the T-cell lymphoma is cutaneous T-cell lymphoma.

11. The method of claim 10 , wherein the cutaneous T-cell lymphoma is mycosis fungoides or Sézary syndrome.

12. The method of claim 1 , further comprising administering to the patient an effective amount of rituximab.

13. The method of claim 1 , wherein the effective amount of cerdulatinib is from about 10 mg to about 45 mg daily.

14. The method of claim 1 , wherein the effective amount of cerdulatinib is from about 15 mg to about 30 mg twice daily.

15. The method claim 1 , wherein the effective amount of cerdulatinib is about 15 mg, 20 mg, 25 mg, or 30 mg twice daily.